Clinical Trials Directory

Trials / Completed

CompletedNCT03429491

Novel Nutrition Solutions for Sarcopenia

Novel Nutrition Solutions in Elderly at Risk of Sarcopenia: LC n-3 PUFA and Leucine Combinations

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
108 (actual)
Sponsor
University College Dublin · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Accepted

Summary

This study will examine the effect of leucine-enriched protein supplementation, alone and in combination with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFA), on muscle mass and function in older adults at risk of sarcopenia. The investigators hypothesize that LC n-3 PUFA supplementation will further enhance the efficacy of the leucine-enriched protein.

Detailed description

The progressive loss of skeletal muscle mass and function with advancing age, termed sarcopenia, contributes substantially to disability, physical dependence, and mortality among older adults. Aging is associated with an attenuated muscle protein synthetic response to the ingestion of small to moderate protein doses compared to younger persons. Several studies have reported that the acute, postprandial muscle protein synthesis (MPS) response to a suboptimal protein dose is enhanced when the leucine content of the protein bolus is increased. This indicates that supplementing the lower-protein daily meals (i.e., breakfast and lunch) with leucine may represent a practical strategy to augment the MPS response to these meals and, subsequently, attenuate sarcopenic muscle mass loss over time. In addition, LC n-3 PUFA supplementation has been shown to enhance the MPS response to amino acid infusion older adults suggesting that combined leucine and LC n-3 PUFA supplementation be particularly effective for improving daily MPS, muscle mass and function in older adults.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPlaceboProtein-free, LC n-3 PUFA-free juice based supplement
DIETARY_SUPPLEMENTLeucine-enriched proteinLeucine-enriched whey protein
DIETARY_SUPPLEMENTLC n-3 PUFALC n-3 PUFA

Timeline

Start date
2017-06-01
Primary completion
2018-12-21
Completion
2018-12-21
First posted
2018-02-12
Last updated
2019-04-18

Locations

1 site across 1 country: Ireland

Source: ClinicalTrials.gov record NCT03429491. Inclusion in this directory is not an endorsement.